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A b s t r a c t
Background: In the era of modern interventional cardiology, implantation of a balloon expandable stent is the finishing touch 
of almost every coronary angioplasty. However, sometimes we face a clinical situation in which the decision regarding the 
stent diameter is complicated, especially in the ectatic part of arteries, in situations when the artery lumen is obscured with 
the thrombus, or when the reference diameter of the proximal and distal part of the lesion vary greatly. That is why the idea 
of a self-apposing stent similar to the one used in peripheral vascular interventions was adopted into cardiology. 
Aim: The aim of this study was to present a single-centre registry of STENTYS® stent implantation in 40 selected patients with 
acute coronary syndromes (ACS) or with stable angina (coronary artery disease [CAD]) treated with this self-expandable stent.
Methods and Results: The device was successfully implanted in all patients. During in-hospital observation and 30-day 
follow-up there were two cases of death, but none of the patients had acute stent thrombosis or ACS ST elevation myocardial 
infarction. In one case ACS type 4b was diagnosed. In all patients the stent was delivered in the target lesion. In two cases the 
procedure was performed in patients with multivessel CAD extending into the left main stem in a state of cardiogenic shock. 
These patients died immediately after the procedure. There were two procedure complications: in one case dissection after 
post dilatation occurred distally to the stent, and in one patient the calcified proximal part of the left anterior descending artery 
was dissected with system passage. Thirty-eight patients survived the 12-month follow-up period, and three (7.8%) patients 
underwent repeated target-lesion revascularisation.
Conclusions: In the presented single-centre registry the STENTYS® stent was used with a high delivery and procedural success 
rate. Satisfactory clinical long-term outcome both in stable patients and ACS patients with a repeated revascularisation ratio 
of 7.8% was observed. The stent design allowed successful treatment of bifurcation lesions. 
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INTRODUCTION
Percutaneous coronary intervention (PCI) with balloon an-
gioplasty and stent implantation is considered as the optimal 
approach for the treatment of patients with coronary artery 
disease (CAD), especially those with acute coronary syndrome 
(ACS) [1]. However, in some groups of patients the results of 
angioplasty even with stent implantation are characterised by 
lower procedural success and worse clinical outcomes [2]. 
These situations include patients with ACS when the lumen 
of the artery is obscured due to thrombus formation or vessel 
contraction, patients with lesions located in the vein graft, or 
those with atypical coronary anatomy [3]. Therefore, there is 
a risk of implantation of an undersized stent, which may lead 
to stent malapposition, which is a primary predictor of stent 
thrombosis and restenosis [4]. On the other hand, stent over-
sizing may also be dangerous, causing vessel wall dissection, 
perforation, and distal embolisation with no-reflow effect. 
Both under- and oversizing of the implanted stent may lead 
to increased risk of adverse clinical events. Intravascular ultra-
sound (IVUS) or optical coherence tomography (OCT)-guided 
angioplasty can easily overcame the mentioned problems [5]. 
However, this procedure in ACS patients may not be covered 
by the national health system in selected countries (e.g. in 
Poland). Therefore, it may be rational to use a stent that has the 
ability to self-expand over time [6]. Interventions in coronary 
bifurcations have significantly higher rates of restenosis. PCI of 
the complex bifurcation lesion not only increases the risk of 
restenosis but also may increase the risk of stent thrombosis 
when some of the stent struts are left unopposed. To overcome 
these limitations the STENTYS® stent has been introduced [7]. 
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The delivery system of this stent is similar to those used in 
peripheral vascular interventions. STENTYS® is characterised 
by a constant outward radial force and it continues to expand 
over time, so the stent is able to adapt itself to the varying 
proximal and distal diameters of the artery. STENTYS® is made 
of nitinol (nickel–titanium alloy) and is deployed by the with-
drawal of a retractable sheath. The stent may be maximally 
expanded up to 7.0 mm diameter. The STENTYS® stent has 
disconnectable interconnections between struts, which can 
be opened with balloon inflation to create side branch (SB) 
access. After the struts open outward the force of the stent 
is directed towards the carina, so a final “kissing balloon” 
technique is not mandatory [8–10]. In the present study we 
were interested in the technical aspects and outcomes of 
STENTYS® stent implantation in a non-randomised group of 
patients selected for the procedure by a physician perform-
ing angioplasty. 
The aim of this study was to present a single-centre regis-
try of the STENTYS® stent implantation in 40 selected patients.
METHODS
This was a single-centre, non-randomised retrospective regis-
try study of 40 patients with ACS or with stable angina (CAD) 
treated with a self-apposing STENTYS® stent hospitalised be-
tween the beginning of 2013 and March of 2015. Metabolic 
disorders like diabetes mellitus or hypercholesterolaemia 
were diagnosed in 38 patients (diabetes mellitus type 2 in 
10 patients, hypercholesterolaemia in 28 patients). Lipid 
lowering therapy was administered in 35 patients including 
rosuvastatin in 20 patients (mean dose 10 mg), atorvastatin 
in eight patients (mean dose of 20 mg daily), and in seven 
cases simvastatin in a dose of 10 mg daily. Ten patients had 
diagnosed diabetes mellitus, and four of them were on insu-
lin therapy. Mean values of glycated haemoglobin (HbA1c) 
indicated optimal glucose lowering therapy in those patients 
(Table 1). Beta-blocker therapy was administered in 37 pa-
tients, angiotensin converting enzyme inhibitors in 33 patients, 
angiotensin receptor blockers in nine patients, diuretics in 
21 patients, and calcium channel blockers in 17 patients.
The use of a STENTYS® stent was left to the discretion 
of the interventional cardiologist performing the procedure. 
If not treated before the procedure, each patient received 
a loading dose of antiplatelet therapy: 300 mg of acetylsali-
cylic acid (ASA), 600 mg clopidogrel, and a heparin bolus of 
100 IU/kg IV. The bolus of glycoprotein IIb/IIIa inhibitor was 
administered in patients with ACS if needed. Use of bivali-
rudin was accepted. After the procedure, patients received 
ASA (75 mg/day) and clopidogrel (75 mg/day for a month or 
for 12 months after the procedure — ST elevation myocardial 
infarction [STEMI], non-ST elevation myocardial infarction 
[NSTEMI] and patients with drug eluting stent [DES]). Predila-
tation of target lesion was performed in all cases. In patients 
with ACS thrombus aspiration was left to the discretion of 
the performing physician. In the case of bifurcation lesion 
with SB ostium covered by stent, stent strut disconnection 
was performed if the diameter of the SB was > 2.5 mm with 
thrombolysis in myocardial infarction (TIMI) flow < 3, with 
proximal stenosis greater than 50% by quantitative coronary 
analysis (QCA). Stent post-dilatation was performed in the case 
of residual stenosis more than 30% in QCA or if incomplete 
stent apposition was found in IVUS. Stents available for use 
were: bare-metal stent (BMS) with a nominal strut width of 
68 μm, and DES with polysulphone polymer eluting paclitaxel. 
Stent lengths used were 22 mm and 27 mm with a diameter 
suitable for vessels with a reference vessel diameter between 
2.5 mm and 4.5 mm. 
The authors declare that the study complies with the 
Declaration of Helsinki. The research protocol was approved 
by the locally appointed Ethics Committee, and informed 
consent of the subjects was obtained. 
Angiographic and IVUS assessment
During the procedure the lesion length, reference vessel diam-
eter in 5-mm segments proximal (PRD) and distal (DRD) to the 
culprit lesion, minimal lumen diameter (MLD), and stenosis 
assessment was performed with the use of QCA software built 
into a Siemens Artis Zee system. From these measurements 
the stenosis diameter was calculated.
Intravascular ultrasound images were acquired with 
a Boston I-lab system and Opticross transducer by motorised 
pull-back at a constant speed of 0.5 mm/s after intracoronary 
administration of 0.2 mg nitroglycerin. Reference segments 
of the index artery were at the points of 5 mm proximal and 
distal to the target lesion. Then the reference external elastic 
membrane (EEM) area was measured with subsequent meas-
urements of the reference lumen area (RLA). RLAs were meas-
ured in segments 5 mm proximal (pRLA) and distal (dRLA) to 
the target lesion. In the target lesion, in the narrowest part, 
the minimal lumen area (MLA) and EEM were measured. The 
percentage of area of stenosis was calculated as (RLA − MLA)/
RLA × 100 (%). The lesion length was measured using the 
motorised pullback device. 
Follow-up timelines
Clinical data was collected and assessed before and after 
the procedure, at discharge, and 6 and 12 months after the 
procedure. The primary endpoint for the study was major 
advance cardiac event (MACE), defined as: death, recurrent 
myocardial infarction (MI), stent thrombosis, urgent target 
vessel revascularisation (TVR), and clinically driven target 
lesion revascularisation (TLR). 
Definitions
Death of the patient was considered cardiac unless a non-car-
diac cause was identified. MI was diagnosed with the third 
universal definition of MI [11]. 
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Target vessel revascularisation was defined as a repeated 
revascularisation (PCI or coronary artery bypass grafting 
[CABG]) of any segment in the target artery. TLR was defined 
as repeat PCI because of restenosis within the stent or within 
the 5-mm segments of the index artery proximal or distal to 
the stent. Stent thrombosis was defined as in the Academic 
Research Consortium definition. 
Technical success was defined as the ability to cross with 
the device and deploy the stent at the target lesion. 
Angiographic success was defined when TIMI flow 3 in 
the index artery was achieved with < 20% of the residual 
stenosis in the target lesion. 
Procedural success was defined as technical and angio-
graphic success in the absence of MACE at hospital discharge. 
Clinical vs. non-clinically driven TLR was defined as 
follows: TLR was defined as clinically-driven if the patient 
had a target lesion diameter stenosis ≥ 50% by QCA and 
clinical symptoms of angina pectoris or proven ischaemia 
with: ischaemic changes in rest electrocardiogram (ECG) or 
in ECG exercise test, or in single-photon emission computed 
tomography or stress echocardiography related to the index 
vessel lesion. In-stent restenosis was defined as the presenta-
tion of > 50% diameter stenosis in the stented segment of 
the target artery in angiogram.
Continuous variables are presented as means ± standard 
deviations, while categorical variables are presented as counts 
and percentages.
RESULTS
A total of 40 patients with clinical evidence of myocardial 
ischaemia and de novo coronary lesions were enrolled, in-
cluding: 18 patients with ACS-STEMI, 11 patients with 
ACS-NSTEMI, and 11 patients with elective PCI in CAD. 
Clinical characteristics of the patients and demographics data 
are displayed in Table 1. Patients were mostly middle-aged 
(61.7 years), male (62%), and with multiple risk factors for 
ischaemic heart disease. The majority of patients had disease 
affecting two or three vessels (67.5%). Target lesions were 
Table1. Demographic and clinical data of patients
Age [years] 61.7 ± 11.2
Female 15 (38%)
Diabetes mellitus 10 (25%)
Mean glucose level [mmol/L] 6.2 ± 1.8
HbA1c [%] 6.8 ± 0.3
Hypertension 29 (72%)
Mean BP systolic values [mm Hg] 130 ± 21
Mean BP diastolic values [mm Hg] 77 ± 9
Smoker (current) 8 (20%)
Body mass index [kg/m2] 27.3 ± 9.7
Previous myocardial infarction 11 (27%)
Ejection fraction (%) (estimated by TTE) 51 ± 11
Hypercholesterolaemia 28 (70%)
Mean total cholesterol [mg/dL] 176 ± 45
Mean LDL [mg/dL] 94 ± 33
Mean HDL [mg/dL] 46 ± 12
Chronic kidney disease (GFR < 60) 3 (7.5%)
Mean eGFR (MDRD mL/min/1.73 m2) 79 ± 19
Total acute coronary syndrome 29 (72%)
NSTEMI 11 (27.5%)
STEMI 18 (45%)
Stable CAD 11 (27.5%)
Prior PCI 13 (32%)
Prior CABG 6 (15%) 
Data are presented as mean ± standard deviation or number and per-
centage (in brackets); CABG — coronary artery bypass graft; CAD — coro-
nary artery disease; BP — blood pressure; eGFR — estimated glomeru-
lar filtration rate; HbA1c — glycated haemoglobin; HDL — high-density 
lipoprotein; LDL — low-density lipoprotein; NSTEMI — acute coronary 
syndrome without ST segment elevation myocardial infarction; PCI — 
percutaneous coronary intervention; STEMI — acute coronary syndro-
me with ST segment elevation; TTE — transthoracic echocardiography
Table 2. Angiographic findings, target lesion characteristic, 
and technical data of the procedures
Multivessel disease 27 (67.5%)
Mean bifurcation angulation [degrees] 59 ± 23
Diameter stenosis [%] 89 ± 14  
(min 75 – max 100%)
Mean lesion length [mm] 20.7 ± 6.2
Technical success 40 (100%)
Device success 37 (96.1%)
Angiographic success 39 (98.9%)
Procedural success 37 (96.1%)
Total mean procedure time [min] 57.8 ± 36.2
Intra-aortic balloon pump 2 (1.9%)
Thrombus aspiration 19 (47.5%)
Post dilatation performed 24 (60%)
Total number of stents used/stent  
per patient ratio
48/1.2
Target lesion additional stent 6 (15%)
Side branch stenting 1 (2.5%)
Radial access 37 (92%)
Primary femoral access 3 (8%)
Conversion from radial to femoral access 2 (5%)
Contrast dose [mL] 165 ± 29
Radiation dose [mGy] 749 ± 95
Data are presented as mean ± standard deviation or number and 
percentage (in brackets)
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mostly in type B or C lesions apart from three cases with 
type A lesions. Table 2 summarises lesion characteristics at 
the baseline. 
A total of 48 stents were used, including 45 STENTYS® 
stents (32 BMS and 13 DES). Post-dilatation of the culprit 
lesion using a noncompliant balloon sized to the vessel ref-
erence diameter was performed in 24 cases. Simultaneous 
kissing balloon technique was performed in 13 patients, and 
in one patient the proximal part of SB was stented because 
of significant stenosis. Thrombus aspiration was performed in 
19 (47.5%) patients: 12 with ACS-STEMI and 7 in ACS-NSTE-
MI. Seventeen patients received glycoprotein IIb/IIIa inhibitors 
(integrillin 12 patients, abciximab 5 patients); despite the 
fact that thrombus aspiration was performed two patient did 
not received glycoprotein IIb/IIIa therapy due to increased 
risk of bleeding (medical history of gastrointestinal bleeding 
within two months prior to admission). Five patients received 
more than one STENTYS® stent because of insufficient lesion 
coverage (four cases) and one because of proximal dissection 
to the previously implanted stent. In three patients an addi-
tional, DES balloon expandable stent was used. The second 
stent was placed to treat a second lesion revealed distally to 
the culprit lesion in one patient, and in one patient SB was 
stented. Finally, in one patient a STENTYS® stent and one ad-
ditional, overlapping conventional DES stent were implanted 
in the left anterior descending artery (LAD). In this patient, 
after reopening of the infarct artery, a STENTYS® stent was 
implanted. IVUS study demonstrated incomplete stent ap-
position in the middle part of the lesion; after post dilatation 
a linear vessel dissection occurred. An entry point (as proven 
by IVUS scan) was located within the middle part of the lesion 
under the stent. To treat the dissection a partially overlapping 
balloon expandable DES stent was placed with TIMI 3 flow. 
Final TIMI 3 flow after stent implantation was achieved in all 
patients but one. In that case there was an angiographic find-
ing of slow flow effect. After intracoronary administration of 
100 µg of adenosine with glycoprotein (GP) IIb/IIIa inhibitors 
administration the TIMI grade score increased to 3. Eight cases 
of ectasia in target vessel were revealed; in those patients 
proper stent apposition was confirmed with IVUS (Figs. 1, 2). 
Amongst patients with bifurcations according to the Medina 
classification [12], 11 (22.5%) patients had disease affecting 
the SB (true bifurcations), and three (7.5%) patients had dis-
ease affecting all three arms (Medina 1.1.1). In all cases SB 
ostium remained wide open after MB stent implantation. One 
lesion was trifurcation including the left main artery (LM/LAD), 
circumflex artery (Cx), and obtuse marginal (OM).
Device success was achieved in all cases. The overall 
procedural success rate was high at 87.5% (37/40 patients) 
with no stent thrombosis. Two patients died immediately after 
PCI procedure. Those were patients with NSTEMI in a state 
of cardiogenic shock before the procedure was started, with 
three-vessel CAD and left main stem (LMS) stenosis. These 
patients were disqualified from CABG treatment by the 
consulting cardiac surgeon. During PCI procedure the opera-
tor was not able to cross the strongly calcified lesions with 
a balloon expandable stent system even after predilatation 
with noncompliant balloons (4.0 × 15–20 atm). Therefore, 
a decision on STENTYS® stent use was made. After STENTYS® 
stent delivery into the target area, in one case trifurcation 
LM/LAD/Cx/intermediate (IM) artery a catheter-induced spiral 
dissection in LM/LAD occurred with closing of both Cx and IM 
arteries. Both Cx and IM ostia were then reopened followed 
by additional balloon expandable DES implantation into the 
dominant Cx with TIMI 3 flow restoration in both branch-
es. STENTYS® stent was deployed in LM/LAD with TIMI 3 
flow. Unfortunately, the patient died immediately after PCI 
in a state of cardiogenic shock with electromechanical dis-
sociation. In the second case (LM-Cx/LAD bifurcation, lesion 
protruding into Cx) the patient suffered from sudden cardiac 
arrest (asystole) during coronarography. After resuscitation 
PCI of LM and LAD ostium was performed with subsequent 
implantation of a STENTYS® stent in the direction of the LM/Cx 
followed by opening of the struts into the LAD. During the 
PCI procedure a second cardiac arrest occurred with asystole 
present in ECG. The procedure was finished with support of 
a LUCAS system, but patient died immediately after the pro-
cedure. The patient with slow flow described above counted 
as the third patient who did not achieve procedural success. In 
this patient, due to troponin level rise, NSTEMI type 4 was 
diagnosed. Table 3 describes the outcome and technical data 
of the PCI procedures.
During initial procedure IVUS assessment was performed 
in 38 patients. Detailed data of IVUS and QCA examination 
are presented in Table 3.
Long-term clinical and angiographic results
Late follow-up at 12 months was available for all 38 pa-
tients. No death or stent thrombosis was reported at long-term 
follow up. Twenty-four patients were free of symptoms 
with negative results of ECG exercise test performed six 
and 12 months after the procedure and therefore were not 
scheduled for repeated coronary angiography. Table 4 shows 
the in-hospital and follow-up data of primary endpoint in the 
studied population. 
Angiographic and IVUS follow-up was available for 
14 patients, including 11 patients hospitalised because of 
second stage of previously planned PCI and three patients 
hospitalised because of ischaemic symptoms or positive results 
of ECG exercise test. In three (7.8%) patients repeated TVR 
due to restenosis was needed. During the index procedure 
those patients had implanted BMS STENTYS® stent, therefore 
during the second procedure they underwent clinically-driven 
TLR. One patient was admitted two months after index hos-
pitalisation, with symptoms of unstable angina pectoris and 
ST segment depression in resting ECG with 40% restenosis 
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Figure 1. Example of STENTYS® stent implantation in patient with acute coronary syndrome (STEMI ACS); A. Acute occlusions of large 
and ectatic circumflex artery with spontaneous recanalisation (B); C. STENTYS® stent deployment; D, E. Post-implantation images
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in previously implanted stent in LM/LAD. That patient was 
treated with a drug-eluting balloon and was free of symp-
toms during the next 10 months. The second patient (index 
lesion located in second marginal branch) was admitted 
three months after procedure due to positive result of ECG 
exercise test (Bruce protocol, 8 Mets with 2.5 mm ST segment 
depression in V4–V6 leads). During second angiography there 
was a 70% in-segment restenosis with the lesion located at 
the distal edge of a previously implanted 2.5/30 × 27 mm 
STENTYS® stent. Restenosis was treated with implantation of 
balloon expandable DES stent 3.0 × 12 mm. The patient was 
symptom free after nine months of follow-up with negative 
result of ECG exercise test at 12 months. A third patient, also 
with positive ECG test (Bruce protocol, 6 Mets with 2.0 mm 
ST segment depression in I, aVL and V5–V6 leads), hospi-
talised four months after index PCI, had in-stent restenosis 
of 60% assessed by QCA. This patient, during repeated PCI 
with a drug-eluting balloon, experienced an NSTEMI (type 4a) 
related to closure of marginal branch ostium (reference SB 
diameter < 2 mm) covered with a previously implanted 
STENTYS® stent. Among the remaining 11 patients who un-
derwent repeated coronary angiography for the next stage 
of PCI, there were no late stent thrombosis or restenosis as 
assessed with QCA and IVUS. The second angiography was 
usually scheduled from 40 to 50 days (44 ± 8 days) after index 
procedure. During second angiography IVUS was performed 
in all patients. Paired QCA and IVUS results of those patients 
showed significant increase of MLD (post PCI) as compared 
to pre-procedural MLD. There was a progressive increase 
in post-procedure MLD and in 5-mm segments of artery 
proximal and distal to the implanted stent in follow-up QCA 
measurement; however, the differences were not statistically 
significant. Detailed results of QCA and IVUS measurements 
in patients with follow-up angiography are shown in Table 5. 
MLA, proximal and distal lumen areas showed a trend to 
increase over time, but the differences were not statistically 
significant. In follow-up IVUS stent malapposition was not 
observed nor incomplete lesion coverage.
DISSCUSSION 
The main finding of this study is that the STENTYS® stent can 
be used with a high delivery and procedural success rate. 
This stent can be used with satisfactory procedural outcome 
in patients with ACS and stable angina pectoris, especially 
in patients with atypical coronary anatomy or with coronary 
bifurcation lesions. We achieved a 100% technical success 
rate, which is high compared to traditional balloon expand-
able stents [9–11]. However, the procedures were not free 
of complications. The use of excessive force in one patient 
caused a serious dissection of LMS. It should be stated that 
despite the different platform construction, which eliminated 
the risk of stent migration during lesion crossing, the use of 
the STENTYS® stent with high forces in highly calcified le-
sions may lead to vessel dissection. The STENTYS® stent is 
not a widely used device. In our site, out of 1360 PCIs only 
45 used this stent, i.e. this type of stent counted for 3.3% 
of procedures. Despite its novel design the implantation 
process varies from balloon expandable stents. Therefore, it 
is preferred mainly by experienced operators. Moreover, not 
every kind of lesion requires a STENTYS® stent. In general 
practice it is used in ectatic arteries, saphenous grafts, and in 
bifurcation lesions. The second issue is the cost–effectiveness 
of the procedure. This stent costs twice as much as the more 
commonly used DES balloon expandable stent, but implan-
tation of a self-expandable stent is reimbursed in the same 
manner as regular stent, so the use of STENTYS® is restricted 
to selected patients. 
The presented study is not the first publication describ-
ing usage of this stent in Poland. In the PubMed database 
there are only two (out of 20 found) registered publications 
regarding STENTYS® from our country. In 2014 Smolka et al. 
[13] described the results of a pilot registry of LMS stenting 
Table 3. Quantitative coronary analysis and intravascular ultrasound (IVUS) parameters in studied patients
Pre PCI Post PCI
Mean Median IQR Mean Median IQR
PRD 5 [mm] 3.3 3.3 0.2 3.4 3.3 0.3
MLD 0.8 0.9 0.5 3.1 3.1 0.2
DRD 5 [mm] 2.3 2.2 0.8 2.7 2.5 0.7
IVUS
pRLA [mm2] 7.7 7.8 2.1 7.9 7.9 1.9
dRLA [mm2] 6.4 6.5 1.2 6.5 6.7 1.1
MLA [mm2] 2.8 2.9 1.5 5.9 5.4 1.8
PCI — percutaneous coronary intervention; IQR — interquartile range; PRD — mean reference vessel diameter in segment 5 mm proximal to the 
target lesion; MLD — minimal lumen diameter; DRD — mean reference vessel diameter in segment 5 mm distal to the target lesion; pRLA —  
reference vessel area in segment 5 mm proximal to the target lesion; dRLA – reference vessel area in segment 5 mm distal to the target lesion; 
MLA — minimal lumen area
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Table 4. Procedure characteristics in the studied group of patients with MACE presentation and number of stents used








MACE STENTYS  
stent type
Other stents  
used
1 NSTEMI 1.1.1 Ostial PD/SO/kissing Death DES
2 NSTEMI 1.1.1 Ostial PD/SO/kissing Death DES
3 NSTEMI 1.1.1 Ostial ASP PD/SO/stent/kissing BMS  1 BES (DES)
4 STEMI 1.1.0 Ectasia ASP/ABX BMS
5 NSTEMI 1.1.0 Ostial PD/SO/kissing DES
6 STEMI 1.1.0 DES
7 CAD 1.1.0 Ostial BMS
8 NSTEMI 1.1.0 Ostial PD/SO/kissing DES
9 STEMI 1.1.0 ASP/INT PD BMS
10 CAD 1.1.0 Ectasia BMS
11 STEMI 1.1.0 ASP/INT DES 1 BES (DES)
12 NSTEMI 1.1.0 Ostial ASP/INT PD/SO/kissing BMS
13 CAD 1.1.0 Restenosis/TLR BMS
14 STEMI 1.1.0 Ectasia ASP/ABX BMS
15 NSTEMI 0.1.1 ASP/INT PD/SO/kissing DES
16 STEMI 0.1.1 PD/SO/kissing BMS
17 CAD 0.1.1 CTO PD/SO/kissing DES
18 STEMI 1.0.1 ASP/INT PD/SO/kissing BMS
19 STEMI 1.0.1 ASP/ABX PD/SO/kissing BMS
20 NSTEMI 0.1.0 Ectasia ASP BMS
21 STEMI 0.1.0 PD DES
22 STEMI 1.0.0 PD 2 BMS
23 NSTEMI 1.0.0 Ectasia Restenosis/ACS 
UA/TLR
BMS
24 CAD 1.0.0 PD BMS
25 CAD 0.0.1 PD/SO/kissing DES
26 STEMI 0.0.1 ASP/INT PD/SO/kissing DES
27 CAD Slow flow/ACS 
type 4
BMS
28 STEMI ASP/ABX 2 BMS
29 STEMI ASP/INT PD BMS
30 STEMI ASP/INT PD BMS
31 CAD Ectasia 2 BMS
32 CAD CTO DES
33 STEMI ASP/INT PD Dissection BMS 1 BES (DES)
34 NSTEMI ASP/INT Restenosis/TLR BMS
35 STEMI BMS
36 CAD Ectasia PD BMS
37 STEMI ASP/ABX PD 2 BMS
38 NSTEMI Ectasia ASP/INT PD BMS
39 CAD CTO 2 DES
40 STEMI ASP/INT PD BMS
ABX — abciximab infusion; ACS – acute coronary syndrome; ASP — thrombus aspiration; BES — balloon expandable stent implantation; Bifurca-
tion/Medina — Medina classification of bifurcation lesion; BMS — bare metal stent; CAD — stable coronary artery disease; CTO — chronic total 
occlusion; DES — drug eluting stent; GP IIb/IIIa — glycoprotein IIb/IIIa inhibitor; INT — integrillin infusion; Kissing — kissing balloon technique; 
MACE — major adverse cardiac events; NSTEMI — acute coronary syndrome without ST segment elevation; PD — post dilatation; SO — struts  
opening; STEMI — acute coronary syndrome with ST segment elevation; TLR — target lesion revascularisation; UA — unstable angina
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in 24 patients with drug-eluting version of the STENTYS® 
stent, with satisfactory results. In our study LMS was stented 
in eight patients with similar technical success; however, as 
described in the text two patients died because of cardiogenic 
shock, and in one patient restenosis occurred in the BMS 
stent. A second study by Mielczarek et al. [14] described 
successful percutaneous angioplasty of the pulmonary vein 
with a self-apposing stent. To our knowledge, in the presented 
manuscript we describe the largest cohort of patients who re-
ceived self-apposing STENTYS® stents documented in Poland.
Incomplete stent apposition related to underestimation of 
artery size is one of the main factors contributing to early stent 
thrombosis. In our study stent thrombosis was not reported 
in patients with ACS nor in patients with stable CAD. The 
Apposition II study proved that in patients with a ACS STEMI 
implantation of self-expandable scaffold was associated with 
significantly better strut apposition as compared to balloon 
expandable stents [10]. Therefore, this should be considered 
as one of the major advantages of the STENTYS® stent. In our 
study incomplete stent apposition was demonstrated with 
IVUS only in one patient with ACS. This issue was resolved 
with high-pressure post-dilatation. Previous studies based 
on OCT and IVUS assessment confirmed the occurrence of 
significant epicardial vasoconstriction in the acute phase of 
ACS. These studies proved that stent under-sizing is a viable 
problem that needs solution [5]. The STENTYS® stent has 
the unique ability to increase its diameter and volume after 
the implantation. The continuous outward force of a self-ex-
pandable stent also prevents elastic recoil of the plaque. In 
our study IVUS examination performed in selected patients 
at an average time of one and half months after index PCI 
showed a small increase in MLD and also an increase in the 
diameter of adjacent artery segments. The most common 
presentation by patients in our study was bifurcation lesion. 
Despite many years of research, there is an ongoing debate 
regarding the  approach to bifurcation lesions [11]. These type 
of lesions need to be treated with PCI in over 20% of patients 
referred for percutaneous transluminal coronary angioplasty. 
PCI of bifurcation is associated with lower procedural success 
and worse clinical outcomes [15]. The recommended strategy 
favours stenting of the main branch with balloon dilatation of 
the SB. This strategy, however, in up to 15% of patients may 
lead to SB ostium stenosis with TIMI flow < 3 with subsequent 
periprocedural infarction. In the NIRVANA study SB occlusion 
during PCI of bifurcation lesions caused periprocedural MI 
in 40% of patients [16]. The differences in STENTYS® stent 
design make possible to disconnect the struts with complete 
carina coverage and creation of easy access to the SB ostium. 
In our study the majority of patients (65%) had bifurcation 
lesion; however, we were forced to stent the SB in just one 
case of patient with post-balloon inflation stenosis > 80% 
extending into the first diagonal branch for 15 mm. Several 
large trials such as the CADILLAC [17], CACTUS [18] have 
proven that in a third of cases of stenting of bifurcation lesions 
a two-stent approach is necessary to avoid the loss of the SB. 
In our study a two-stent strategy was used only once, so these 
data may indicate on the potential benefits of the use of the 
STENTYS® stent in bifurcation lesions. Despite the fact that 
the implantation technique of the STENTYS® stent version 
used in this study needs more care and attention than with 
balloon expandable stents, only short training was needed and 
it was possible to implant the device in the desired location 
in each case. Since, before release, the stent is covered under 
the retractable sheet, it is almost impossible to lose it when 
passing the lesion, even calcified ones. However, excessive 
forces used when crossing the lesion may cause a dissection.
Limitations of the study
The main limitation of the study is the limited number of 
patients included. It was non-randomised retrospective study. 
Table 5. Quantitative coronary analysis and intravascular ultrasound (IVUS) parameters of 14 paired patients who underwent 
repeated angiography
Pre PCI Post PCI Follow up
Mean Median IQR Mean Median IQR Mean Median IQR
PRD 5 [mm] 3.5 3.5 0.2 3.6 3.6 0.2 3.6 3.6 0.2
MLD 0.8* 0.9 0.7 3.2** 3.1 0.5 3.1** 3.1 0.5
DRD 5 [mm] 2.8 2.8 0.6 2.9 2.9 0.8 2.9 2.9 0.6
IVUS
pRLA [mm2] 7.8 7.6 1.3 7.9 7.8 1.4 8.1 8 2
dRLA [mm2] 6.5 6.5 0.9 6.6 6.7 0.7 7.5 7.2 2.1
MLA [mm2] 2.8* 2.9 0.8 5.9** 5.3 1.9 6.7** 5.5 2.4
*Pre PCI vs. post PCI and follow-up: p < 0.01; **Post PCI vs. follow-up: p = NS; PCI — percutaneous coronary intervention; IQR — interquartile 
range; PRD — mean reference vessel diameter in segment 5 mm proximal to the target lesion; MLD — minimal lumen diameter; DRD — mean  
reference vessel diameter in segment 5 mm distal to the target lesion; pRLA — reference vessel area in segment 5 mm proximal to the target lesion; 
dRLA – reference vessel area in segment 5 mm distal to the target lesion; MLA — minimal lumen area
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We did not perform direct comparison with balloon expand-
able stents. The study group was heterogeneous, including 
patients with ACS and those with stable CAD, so some 
mechanisms of observed MACE were different e.g. cardio-
genic shock leading to death compared to in-stent restenosis 
in follow-up. These observations made statistical analysis 
pointless and direct comparison of patients with MACE to 
those with event-free survival was abandoned. 
CONCLUSIONS
In the presented single-centre registry STENTYS® stents were 
used with a high delivery and procedural success rate. Sat-
isfactory clinical long-term outcome both in stable patients 
and ACS-patients with the TVR ratio of 7.8% was observed. 
Then stent design allowed successful treatment of bifurca-
tion lesions. 
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Stenty samorozprężalne STENTYS w codziennej 
praktyce kardiologa interwencyjnego
Michał Kidawa, Krzysztof Chiżyński, Michał Kacprzak, Anna Ledakowicz-Polak, Marzenna Zielińska
Klinika Intensywnej Terapii Kardiologicznej, Katedra Kardiologii Interwencyjnej i Elektroterapii, Uniwersytet Medyczny w Łodzi, Łódź
S t r e s z c z e n i e
Wstęp: Zabieg angioplastyki naczyń wieńcowych (PCI) jest uznaną metodą leczenia choroby wieńcowej. Jednak u niektórych 
pacjentów ze złożoną morfologią naczyń wieńcowych jest niezmiernie trudno oszacować referencyjną średnicę naczynia. 
Dlatego też wydaje się, że użycie stentów samorozprężalnych, które adaptują się do średnicy naczynia, może być korzystne. 
Cel: Celem pracy była ocena zabiegów PCI wykonanych z wykorzystaniem stentu samorozprężalnego STENTYS®. 
Metody i Wyniki: Grupę badaną stanowiło 40 pacjentów z chorobą wieńcową stabilną i z różnymi postaciami ostrych ze-
społów wieńcowych (ACS), u których implantowano stent STENTYS®. Stent wszczepiono wszystkim pacjentom. W trakcie 
obserwacji krótkoterminowej 2 osoby zmarły zaraz po wykonaniu PCI — byli to chorzy z krytycznym zwężeniem pnia lewej 
tętnicy wieńcowej, we wstrząsie kardiogennym i zdyskwalifikowani z zabiegu pomostowania aortalno-wieńcowego. Ponadto 
u jednego z pozostałych pacjentów rozpoznano zawał serca typu 4b, a u dwóch chorych w trakcie implantacji wystąpiła 
dysekcja naczynia wymagająca założenia kolejnego stentu. Pomimo opisywanych powikłań u wszystkich chorych z badanej 
grupy stent został zaimplantowany w miejscu wybranym przez operatora. W trakcie długoterminowej obserwacji zanotowano 
konieczność ponownej rewaskularyzacji u 3 (7,8%) pacjentów w stentach STENTYS BMS. Nie wystąpiła restenoza w stentach 
STENTYS DES, nie zaobserwowano zakrzepicy w stentach DES/BMS.
Wnioski: Stent samorozprężalny STENTYS® umożliwia wykonywanie zabiegów angioplastyki u pacjentów ze złożoną mor-
fologią zmian miażdżycowych. Charakteryzuje się niskim odsetkiem konieczności powtórnej rewaskularyzacji i dobrymi 
wynikami odległymi.
Słowa kluczowe: angioplastyka wieńcowa, ektazja naczyń wieńcowych, stent samorozprężalny
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